Findings

What do systematic reviews say?

3 questions · 3 findings · 1 reviews

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 1 · 33.3%High 2 · 66.7%

Tumour response · people with metastatic CRC

Irinotecan + oxaliplatin probably leads to higher overall tumour response compared with irinotecan (moderate certainty).

1 finding from 1 review

Second‐line systemic therapy for metastatic colorectal cancer 2017 · Cochrane Headline outcomes only
RR 2.98 [1.91, 4.64]
1 study · 627 participants
Moderate

Tumour response · people with metastatic CRC

Irinotecan‐based regimens leads to higher overall tumour response compared with irinotecan (high certainty).

1 finding from 1 review

Second‐line systemic therapy for metastatic colorectal cancer 2017 · Cochrane Headline outcomes only
RR 2.87 [2.1, 3.93]
6 studies · 2577 participants
High

Tumour response · people with metastatic CRC

Irinotecan + targeted therapy leads to higher overall tumour response compared with irinotecan (high certainty).

1 finding from 1 review

Second‐line systemic therapy for metastatic colorectal cancer 2017 · Cochrane Headline outcomes only
RR 3.38 [2.53, 4.52]
2 studies · 1758 participants
High